Bulgaria-based CRO August Research adds new sites in Georgia and Moldova

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/FilmColoratStudio)
(Image: Getty/FilmColoratStudio)

Related tags: CRO, Contract research, Clinical trials

August Research is adding clinical trial operations in Georgia and Moldova, expanding the CRO’s reach in Central and Eastern Europe – a less developed market with “fewer competitive trials and lower costs,” says CEO.

The niche contract research organization (CRO) August Research is headquartered in Sofia, Bulgaria, with operations in Croatia, Czech Republic, Hungary, Poland, Romania, Serbia, and Slovakia. 

The company this month has added operations in the country of Georgia and Moldova via an acquisition from the Pittsboro, NC-based CRO SPRI Clinical Trials. Financial terms were not disclosed.

Dana Leff Niedzielska, CEO of August Research, said the opportunity arose as SPRI was “winding down”​ operations in these countries. The acquisition was “a great way to get started there with an existing operation, ongoing projects, and staff,”​ she told us.

August Research will be keeping all local employees on staff and will integrate operations into its existing structure. The company’s senior managers based in Sofia will oversee the new locations “in the same way that we manage all our individual country operations,”​ explained Niedzielska.

Operating outside the EU

According to Niedzielska, Central and Eastern European countries are becoming increasingly popular destinations for conducting global clinical trials, due to faster enrollment times and lower costs as compared to Western Europe or the US.

“As the more developed countries become saturated with trials and more expensive, sponsors consider additional markets where there are fewer competitive trials and lower costs,”​ she told us.

“In the case of Georgia, the government has created a very fast clinical trial approval process to further encourage the conduct of clinical trials in the country,”​ Niedzielska added, “Currently, the timelines for regulatory approval in Georgia are significantly shorter than in the European Union.”

Niedzielska also noted that both Georgia and Moldova are outside of the European Union (EU), and as such are not required to follow EU Clinical Trial Regulations. She said, “For study sponsors who do not have the required trial documentation to run trials in the EU, working on the European Continent outside of the EU can be a great option.”

The company does not currently have plans to expand into additional countries in Central and Eastern Europe. However, Niedzielska said the company hopes to grow its existing operations through additional trial volume in the coming 1-2 years.

“While our infrastructure and focus is on Central and Eastern Europe (because we believe it is the most efficient region for conducting clinical trials) we also have a team of freelance CRAs in Western Europe, so we can provide services for our clients across Europe,”​ she added.

“By combining the locally based CRAs with our in-house regulatory and administrative support staff, we are able to offer our clients European-wide coverage for their clinical trials.”

Related news

Show more

Related products

show more

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Manufacturing Cyto and Non-Cyto Drugs in One Facility

Baxter BioPharma Solutions | 01-Mar-2020 | Technical / White Paper

Recent market reports suggest increasing product niches, which may lead to decreasing numbers of units per product, making dedicated facilities less practical....

Related suppliers

Follow us


View more